Form 4: ResMed CFO Reports Stock Transaction Under 10b5-1 Plan
Statement of Changes in Beneficial Ownership
ResMed Inc. Chief Financial Officer Brett Sandercock executed a transaction involving 1,000 shares of common stock under a pre-established Rule 10b5-1 trading plan.
Summary
- Brett Sandercock, Chief Financial Officer of ResMed Inc., reported a transaction on April 1, 2026.
- The transaction involved the acquisition of 1,000 shares of ResMed Common Stock at a price of $224.31 per share.
- This transaction was executed under a Rule 10b5-1 trading plan that was adopted on February 19, 2025.
- Following this transaction, Sandercock beneficially owns 83,495 shares of ResMed Common Stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it reports a routine transaction under a pre-established plan by an executive, without providing new financial information or strategic insights.
Positives
- The transaction was conducted under a pre-defined Rule 10b5-1 plan, indicating adherence to a structured and pre-planned trading strategy.
- The CFO continues to hold a significant number of shares (83,495) directly, suggesting continued personal investment in the company.
Risks
- The Rule 10b5-1 plan, while providing an affirmative defense against insider trading allegations, still involves the sale of company stock by a key executive, which could be perceived negatively by the market if not contextualized.
- The sale price of $224.31 per share may indicate a point at which the executive believes the stock is fairly valued or has reached a target price for their plan.
Future Outlook
The filing does not contain forward-looking statements or guidance. It solely reports a past transaction.
Industry Context
StockSavvy.ai notes that the use of Rule 10b5-1 plans by executives is a common practice to diversify their holdings or meet financial needs while mitigating concerns about insider trading. This filing indicates ResMed's CFO is utilizing such a plan.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Rule 10b5-1 Plan Transaction | A transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). | 04/01/2026 | Demonstrates adherence to established corporate governance policies for insider trading compliance. |
Stakeholder Impact
- Shareholders: The transaction itself does not directly impact shareholders, but the adherence to a Rule 10b5-1 plan provides assurance regarding compliance with insider trading regulations.
- Management: Confirms the CFO's continued engagement with the company's stock through a structured trading plan.
Key Dates
| Date | Description |
|---|---|
| 02/19/2025 | Date the Rule 10b5-1 trading plan was adopted. |
| 04/01/2026 | Date of the reported stock transaction. |
| 04/02/2026 | Date the Form 4 was signed by the reporting person. |
Keywords
ResMed Inc., RMD, Form 4, Insider Trading, Rule 10b5-1, Brett Sandercock, Chief Financial Officer, Stock Transaction, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.